Credit Suisse Group set a $45.00 price objective on Aimmune Therapeutics (NASDAQ:AIMT) in a research report released on Thursday. The brokerage currently has a buy rating on the biotechnology company’s stock.
Several other research firms have also recently weighed in on AIMT. Zacks Investment Research raised Aimmune Therapeutics from a sell rating to a hold rating in a report on Monday, October 16th. Piper Jaffray Companies set a $38.00 price target on Aimmune Therapeutics and gave the company a buy rating in a report on Saturday, October 21st. Wedbush reaffirmed an outperform rating and issued a $70.00 price target (up previously from $42.00) on shares of Aimmune Therapeutics in a report on Monday, October 23rd. Roth Capital initiated coverage on Aimmune Therapeutics in a report on Monday, November 20th. They issued a buy rating and a $60.00 price target on the stock. Finally, ValuEngine cut Aimmune Therapeutics from a hold rating to a sell rating in a report on Friday, December 1st. Two investment analysts have rated the stock with a sell rating, one has assigned a hold rating and six have given a buy rating to the company. Aimmune Therapeutics currently has an average rating of Hold and a consensus target price of $55.43.
Shares of Aimmune Therapeutics (NASDAQ:AIMT) opened at $39.43 on Thursday. The stock has a market capitalization of $2,005.55, a PE ratio of -16.78 and a beta of -0.66. Aimmune Therapeutics has a 1-year low of $15.97 and a 1-year high of $40.00.
Aimmune Therapeutics (NASDAQ:AIMT) last issued its quarterly earnings data on Monday, November 6th. The biotechnology company reported ($0.63) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.72) by $0.09. analysts anticipate that Aimmune Therapeutics will post -2.51 earnings per share for the current year.
In related news, insider Douglas T. Sheehy sold 1,648 shares of the firm’s stock in a transaction dated Thursday, January 4th. The stock was sold at an average price of $37.33, for a total transaction of $61,519.84. Following the transaction, the insider now directly owns 1,648 shares of the company’s stock, valued at approximately $61,519.84. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, insider Susan E. Barrowcliffe sold 75,000 shares of the firm’s stock in a transaction dated Tuesday, January 2nd. The shares were sold at an average price of $37.14, for a total value of $2,785,500.00. The disclosure for this sale can be found here. In the last ninety days, insiders sold 136,792 shares of company stock worth $4,960,908. Insiders own 17.59% of the company’s stock.
Several hedge funds and other institutional investors have recently made changes to their positions in AIMT. Citadel Advisors LLC raised its holdings in shares of Aimmune Therapeutics by 3,092.5% during the 3rd quarter. Citadel Advisors LLC now owns 559,641 shares of the biotechnology company’s stock valued at $13,873,000 after buying an additional 542,111 shares in the last quarter. Vanguard Group Inc. raised its holdings in shares of Aimmune Therapeutics by 12.6% during the 2nd quarter. Vanguard Group Inc. now owns 2,476,836 shares of the biotechnology company’s stock valued at $50,923,000 after buying an additional 276,978 shares in the last quarter. State Street Corp raised its holdings in shares of Aimmune Therapeutics by 26.6% during the 2nd quarter. State Street Corp now owns 1,087,320 shares of the biotechnology company’s stock valued at $22,351,000 after buying an additional 228,429 shares in the last quarter. Goldman Sachs Group Inc. raised its holdings in shares of Aimmune Therapeutics by 139.9% during the 2nd quarter. Goldman Sachs Group Inc. now owns 227,377 shares of the biotechnology company’s stock valued at $4,675,000 after buying an additional 132,603 shares in the last quarter. Finally, Palo Alto Investors LLC raised its holdings in shares of Aimmune Therapeutics by 9.9% during the 2nd quarter. Palo Alto Investors LLC now owns 1,289,719 shares of the biotechnology company’s stock valued at $26,517,000 after buying an additional 116,221 shares in the last quarter. 73.34% of the stock is currently owned by institutional investors.
ILLEGAL ACTIVITY WARNING: “Credit Suisse Group Analysts Give Aimmune Therapeutics (AIMT) a $45.00 Price Target” was first posted by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are viewing this news story on another publication, it was illegally stolen and reposted in violation of US and international copyright and trademark law. The correct version of this news story can be viewed at https://www.dispatchtribunal.com/2018/01/15/credit-suisse-group-analysts-give-aimmune-therapeutics-aimt-a-45-00-price-target.html.
Aimmune Therapeutics Company Profile
Aimmune Therapeutics, Inc is a clinical-stage biopharmaceutical company developing a therapeutic approach, including the development of product candidates, for the treatment of peanut and other food allergies. The Company’s therapeutic approach, which it refers to as Characterized Oral Desensitization Immunotherapy (CODIT), is a system designed to desensitize patients to food allergens using characterized biologic products, defined treatment protocols and support services.
Receive News & Ratings for Aimmune Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aimmune Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.